72 related articles for article (PubMed ID: 9398659)
21. C/EBPdelta expression in a BCR-ABL-positive cell line induces growth arrest and myeloid differentiation.
Gery S; Tanosaki S; Hofmann WK; Koppel A; Koeffler HP
Oncogene; 2005 Feb; 24(9):1589-97. PubMed ID: 15674331
[TBL] [Abstract][Full Text] [Related]
22. c-Jun blocks cell differentiation but not growth inhibition or apoptosis of chronic myelogenous leukemia cells induced by STI571 and by histone deacetylase inhibitors.
Huang HM; Liu JC
J Cell Physiol; 2009 Mar; 218(3):568-74. PubMed ID: 19006173
[TBL] [Abstract][Full Text] [Related]
23. FLI-1 inhibits differentiation and induces proliferation of primary erythroblasts.
Pereira R; Quang CT; Lesault I; Dolznig H; Beug H; Ghysdael J
Oncogene; 1999 Feb; 18(8):1597-608. PubMed ID: 10102630
[TBL] [Abstract][Full Text] [Related]
24. Spi-1/PU.1 but not Fli-1 inhibits erythroid-specific alternative splicing of 4.1R pre-mRNA in murine erythroleukemia cells.
Théoleyre O; Deguillien M; Morinière M; Starck J; Moreau-Gachelin F; Morlé F; Baklouti F
Oncogene; 2004 Jan; 23(4):920-7. PubMed ID: 14647452
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells.
Huang M; Dorsey JF; Epling-Burnette PK; Nimmanapalli R; Landowski TH; Mora LB; Niu G; Sinibaldi D; Bai F; Kraker A; Yu H; Moscinski L; Wei S; Djeu J; Dalton WS; Bhalla K; Loughran TP; Wu J; Jove R
Oncogene; 2002 Dec; 21(57):8804-16. PubMed ID: 12483533
[TBL] [Abstract][Full Text] [Related]
26. Suppression of bcr-abl synthesis by siRNAs or tyrosine kinase activity by Glivec alters different oncogenes, apoptotic/antiapoptotic genes and cell proliferation factors (microarray study).
Zhelev Z; Bakalova R; Ohba H; Ewis A; Ishikawa M; Shinohara Y; Baba Y
FEBS Lett; 2004 Jul; 570(1-3):195-204. PubMed ID: 15251464
[TBL] [Abstract][Full Text] [Related]
27. Accumulation of gamma-globin mRNA and induction of irreversible erythroid differentiation after treatment of CML cell line K562 with new doxorubicin derivatives.
Szulawska A; Arkusinska J; Czyz M
Biochem Pharmacol; 2007 Jan; 73(2):175-84. PubMed ID: 17097070
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of Friend cells proliferation by spi-1 antisense oligodeoxynucleotides.
Delgado MD; Hallier M; Meneceur P; Tavitian A; Moreau-Gachelin F
Oncogene; 1994 Jun; 9(6):1723-7. PubMed ID: 8183568
[TBL] [Abstract][Full Text] [Related]
29. Gamma-interferon upregulates transferrin receptors and decreases membrane microviscosity in K562 cells.
Iwagaki H; Marutaka M; Yoshino T; Cao L; Sakuma I; Uomoto M; Takeuchi Y; Tanaka N
Res Commun Mol Pathol Pharmacol; 1996 May; 92(2):191-200. PubMed ID: 8774072
[TBL] [Abstract][Full Text] [Related]
30. Regulation of gene expression by tumor necrosis factor-alpha and interferon-gamma in chronic myelogenous leukemia.
Seong D; Sims SS; Johnson E; Swan F; Lyding J; Lopez A; Talpaz M; Kantarjian H; Emerson S; Lopez-Berestein G
Trans Assoc Am Physicians; 1990; 103():236-41. PubMed ID: 2132534
[No Abstract] [Full Text] [Related]
31. Tumor suppressor activity of the human consensus type I interferon gene.
Geng Y; Yu D; Blatt LM; Taylor MW
Cytokines Mol Ther; 1995 Dec; 1(4):289-300. PubMed ID: 9384682
[TBL] [Abstract][Full Text] [Related]
32. [K562 cells differentiation induced by RNA from rabbit reticulocytes].
Zu S; Gao C; Qiang L
Zhonghua Yi Xue Za Zhi; 1996 Mar; 76(3):191-3. PubMed ID: 8758426
[TBL] [Abstract][Full Text] [Related]
33. Down-regulation of hematopoiesis master regulator PU.1 via aberrant methylation in chronic myeloid leukemia.
Yang H; Liang H; Yan JS; Tao R; Hao SG; Ma LY
Int J Hematol; 2012 Jul; 96(1):65-73. PubMed ID: 22674382
[TBL] [Abstract][Full Text] [Related]
34. Effects of the antisense v-myb' expression on K562 human leukemia cell proliferation and differentiation.
Kamano H; Ohnishi H; Tanaka T; Ikeda K; Okabe A; Irino S
Leuk Res; 1990; 14(10):831-9. PubMed ID: 1979645
[TBL] [Abstract][Full Text] [Related]
35. Correlation of PU.1 and signal regulatory protein α1 expression in PU.1 transgenic K562 cells.
Iseki Y; Nakahara M; Kubo M; Obata F; Harigae H; Takahashi S
Int J Mol Med; 2012 Feb; 29(2):319-23. PubMed ID: 22075620
[TBL] [Abstract][Full Text] [Related]
36. Cell membrane fluidity in K562 cells and its relation to receptor expression.
Iwagaki H; Marutaka M; Nezu M; Suguri T; Tanaka N; Orita K
Res Commun Mol Pathol Pharmacol; 1994 Aug; 85(2):141-9. PubMed ID: 7994558
[TBL] [Abstract][Full Text] [Related]
37. The transcription factor Spi-1/PU.1 interacts with the potential splicing factor TLS.
Hallier M; Lerga A; Barnache S; Tavitian A; Moreau-Gachelin F
J Biol Chem; 1998 Feb; 273(9):4838-42. PubMed ID: 9478924
[TBL] [Abstract][Full Text] [Related]
38. PU.1 exhibits partial functional redundancy with Spi-B, but not with Ets-1 or Elf-1.
Garrett-Sinha LA; Dahl R; Rao S; Barton KP; Simon MC
Blood; 2001 May; 97(9):2908-12. PubMed ID: 11313289
[TBL] [Abstract][Full Text] [Related]
39. Truncated c-Myb expression in the human leukemia cell line TK-6.
Tomita A; Watanabe T; Kosugi H; Ohashi H; Uchida T; Kinoshita T; Mizutani S; Hotta T; Murate T; Seto M; Saito H
Leukemia; 1998 Sep; 12(9):1422-9. PubMed ID: 9737692
[TBL] [Abstract][Full Text] [Related]
40. Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene.
Holtschke T; Löhler J; Kanno Y; Fehr T; Giese N; Rosenbauer F; Lou J; Knobeloch KP; Gabriele L; Waring JF; Bachmann MF; Zinkernagel RM; Morse HC; Ozato K; Horak I
Cell; 1996 Oct; 87(2):307-17. PubMed ID: 8861914
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
